Home / People / Jane Hollywood
Portrait of Jane Hollywood

Jane Hollywood

Partner
Patent Attorney

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Jane is a Partner, UK Chartered Patent Attorney and European Patent Attorney. She is a Life Science specialist working with companies to obtain patent protection and providing advice on all aspects of patent strategy. Jane is also experienced in opposition and appeal proceedings before the European Patent Office, where she has represented clients across a range of life science technologies, most notably in relation to biologics, formulations and genetic engineering.  

In the transgenic field, Jane has worked for many years with Kymab, handling drafting, multi-jurisdictional patent prosecution and opposition matters at the European Patent Office. This subject matter is of great technical complexity, relating to the technology underlying Kymab’s transgenic mouse platform including gene editing techniques. These cases are coordinated alongside national litigation relevant to Kymab’s antibody discovery platform. Jane also has extensive experience in the cell therapy sector having represented companies such as Athersys and International Stem Cell Corporation in relation to obtaining patent protection for their products.

This experience has led to Jane having a particular interest in genetic engineering technologies and their application in gene and cell therapies, sustainable food technologies and agriculture and she works with both established and start-up companies in these areas. With a PhD in plant sciences, she also works with companies in the burgeoning cannabis sector providing strategy advice and assisting them in navigating the complex situation at the European Patent Office to successfully obtain patent protection.

Jane co-manages CMS’s equIP Life Sciences programme, which supports early/growth stage life sciences business. She is also an Expert-In-Residence providing support to start-ups at the Imperial Enterprise Lab.

more less

"Jane Hollywood is very approachable, very invested, and goes the extra mile." Tier 1: PATMA Patent Attorney.

Legal 500, 2022

Also holding a PhD - ….. Hollywood “has a huge amount of technical expertise. She always explains everything extremely thoroughly and gives a good overview of all the key factors”.

IAM Patent 1000, 2021

“Biotech specialist Hollywood is also one to watch, thanks to the foothold she is carving in burgeoning fields such as plant sciences and the nascent cannabis industry.”

IAM Patent 1000, 2020

Education

  • 2008 – European and UK Patent Attorney
  • 2003 – PhD, UCL, London
  • 2000 – BSc Biology, University of Bristol
more less

Feed

17/11/2021
What is a pat­ent and what can I do with it?
Ima­gine, you have de­veloped an AI led dia­gnost­ic tool which provides on­co­lo­gists with a per­cent­age score of how likely it is that a pa­tient’s mole is can­cer­ous. You want to com­mer­cial­ise it, but how do you stop oth­ers from copy­ing your in­ven­tion without your per­mis­sion and com­pet­ing against you? How broad is the pro­tec­tion offered and how long does it last? Should you share the de­tails of your in­ven­tion to po­ten­tial in­vestors (or oth­er third parties) be­fore you have ob­tained a gran­ted pat­ent? Is your in­ven­tion even cap­able of be­ing pro­tec­ted by a pat­ent? Our ex­pert pat­ent team an­swer key ques­tions that in­vent­ors in sim­il­ar situ­ations should con­sider be­fore launch­ing a new product.If you would like to dis­cuss pat­ents in more de­tail, please get in touch. To read the in­tro­duc­tion to pat­ents pa­per down­load the pdf be­low.  
28/10/2021
Arm­chair in­ven­tions: plaus­ib­il­ity at the EPO
Will it get harder to use post-filed data at the European Pat­ent Of­fice (EPO)? The is­sue of plaus­ib­il­ity has now been form­ally re­ferred to the highest ju­di­cial au­thor­ity at the EPO to cla­ri­fy the cir­cum­stances...
06/09/2021
Trans­fer of IP rights in the United King­dom (and EPO where ap­plic­able)
Pat­ents: As­sign­ment 1. How may a pat­ent be as­signed (by law and/or trans­ac­tion) and is it re­quired to re­cord the as­sign­ment in the na­tion­al pat­ent re­gister to be­come ef­fect­ive?  A pat­ent can be trans­ferred...
Comparable
13/05/2021
Can­nabis law and le­gis­la­tion in the UK
Med­ic­al use It is in prin­ciple law­ful to pro­duce, sup­ply, of­fer to sup­ply, im­port, ex­port, have in pos­ses­sion or cul­tiv­ate (in the case of the plant) can­nabis products, in­clud­ing medi­cin­al products...
24/02/2021
COV­ID and ViCo: EPO re­fer­ral to the En­larged Board of Ap­peal
In the last year, the COV­ID-19 pan­dem­ic has res­ul­ted in a large pro­por­tion of the leg­al sec­tor trans­ition­ing to a ‘work from home’ ar­range­ment, with meet­ings tak­ing place re­motely. Non-es­sen­tial travel...
23/12/2020
Where does your Christ­mas din­ner come from… and where will it come from...
Sir Dav­id At­ten­bor­ough caused a sen­sa­tion when he joined In­s­tagram in Septem­ber 2020 and broke the re­cord for be­ing the fast­est ac­count to reach one mil­lion fol­low­ers. He is ur­ging us all to cut down...
14/09/2020
An EPO Case Law Round-Up: Ad­ded Mat­ter
The EPO is well-known for its strict ap­proach to as­sess­ing amend­ments un­der the ad­ded mat­ter pro­vi­sion of Art­icle 123 of the European Pat­ent Con­ven­tion. This of­ten cre­ates com­plex leg­al scen­ari­os which...
13/08/2020
Sus­tain­able food pro­gress may close glob­al reg­u­lat­ory gap
In­nov­a­tion in the sus­tain­able food sec­tor is for­ging ahead at a re­mark­able pace. Our cur­rent food sources ac­count for nearly one-third of glob­al GHG emis­sions while con­sumers are in­creas­ingly bet­ter edu­cated...
19/05/2020
Not Pat­entable – The end of the line for plants and an­im­als pro­duced by...
The highest ju­di­cial au­thor­ity at the EPO is­sued their opin­ion late last week in the con­tro­ver­sial G3/19 (Pep­per) case. Con­trary to pre­vi­ous de­cisions in G2/12 and G2/13 (To­mato/Broc­coli), the En­larged...
15/01/2020
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
17/12/2019
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally...
24/09/2019
AI in dia­gnos­is – pat­ent pro­tec­tion
In this art­icle, we take a closer look at pat­ent pro­tec­tion in Europe for de­vel­op­ments of AI in dia­gnost­ic ap­plic­a­tions. There is enorm­ous po­ten­tial for the use of AI in dia­gnos­is and this is re­flec­ted...